FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008933596> ?p ?o ?g. }

• W2008933596 endingPage "2597" @default.
• W2008933596 startingPage "2592" @default.
• W2008933596 abstract "Abstract BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in 35–45% of patients with CML in chronic phase who receive standard‐dose imatinib. Myelosuppression results in treatment interruptions, which may compromise responses to imatinib. The authors investigated the ability of granulocyte–colony‐stimulating factor (filgrastim) to reverse imatinib‐associated neutropenia, thereby allowing for more continuous imatinib administration. METHODS Thirteen patients with chronic‐phase CML and Grade ≥ 3, imatinib‐induced neutropenia were treated with filgrastim. Treatment with filgrastim was initiated after a median of 22 months from the start of imatinib. Eleven patients received filgrastim 5 μg/kg 1–3 times weekly, and 2 patients received filgrastim 5 μg/kg daily; doses were titrated to maintain an absolute neutrophil count (ANC) ≥ 10 9 /L. RESULTS Seven of 11 patients (64%) who began treatment with an ANC < 1.5 × 10 9 /L had responses (i.e., their ANC improved to ≥ 2 × 10 9 /L within 21 days); the other 4 patients experienced slower recovery but were able to continue receiving imatinib uninterrupted. Before filgrastim administration was initiated, patients did not receive imatinib (due to neutropenia‐related treatment interruptions) for an average of 21% of the total time since the start of imatinib. This figure decreased to 6% after the start of filgrastim treatment ( P = 0.0008). Before filgrastim treatment was initiated, only one patient had achieved a major (partial) cytogenetic response. After the start of filgrastim treatment, five patients had major cytogenetic responses (including two complete responses). CONCLUSIONS The authors concluded that filgrastim may overcome imatinib‐associated neutropenia and allow improved delivery of imatinib. Some patients may experience improvements in their responses to therapy as a result. Cancer 2004. © 2004 American Cancer Society." @default.
• W2008933596 created "2016-06-24" @default.
• W2008933596 creator A5006104041 @default.
• W2008933596 creator A5011529063 @default.
• W2008933596 creator A5015140142 @default.
• W2008933596 creator A5019337932 @default.
• W2008933596 creator A5057701424 @default.
• W2008933596 creator A5061026876 @default.
• W2008933596 creator A5090435894 @default.
• W2008933596 date "2004-06-02" @default.
• W2008933596 modified "2023-10-15" @default.
• W2008933596 title "Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia" @default.
• W2008933596 cites W1531963607 @default.
• W2008933596 cites W2011474502 @default.
• W2008933596 cites W2013850642 @default.
• W2008933596 cites W2016086822 @default.
• W2008933596 cites W2028959752 @default.
• W2008933596 cites W2032810402 @default.
• W2008933596 cites W2041655620 @default.
• W2008933596 cites W2051360772 @default.
• W2008933596 cites W2079446921 @default.
• W2008933596 cites W2091363481 @default.
• W2008933596 cites W2091653492 @default.
• W2008933596 cites W2097255369 @default.
• W2008933596 cites W2119626196 @default.
• W2008933596 cites W2134094496 @default.
• W2008933596 cites W2142969636 @default.
• W2008933596 cites W2151968496 @default.
• W2008933596 cites W2171722798 @default.
• W2008933596 cites W27031567 @default.
• W2008933596 cites W4248663651 @default.
• W2008933596 doi "https://doi.org/10.1002/cncr.20285" @default.
• W2008933596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15540243" @default.
• W2008933596 hasPublicationYear "2004" @default.
• W2008933596 type Work @default.
• W2008933596 sameAs 2008933596 @default.
• W2008933596 citedByCount "52" @default.
• W2008933596 countsByYear W20089335962012 @default.
• W2008933596 countsByYear W20089335962013 @default.
• W2008933596 countsByYear W20089335962015 @default.
• W2008933596 countsByYear W20089335962016 @default.
• W2008933596 countsByYear W20089335962018 @default.
• W2008933596 countsByYear W20089335962020 @default.
• W2008933596 countsByYear W20089335962021 @default.
• W2008933596 countsByYear W20089335962022 @default.
• W2008933596 countsByYear W20089335962023 @default.
• W2008933596 crossrefType "journal-article" @default.
• W2008933596 hasAuthorship W2008933596A5006104041 @default.
• W2008933596 hasAuthorship W2008933596A5011529063 @default.
• W2008933596 hasAuthorship W2008933596A5015140142 @default.
• W2008933596 hasAuthorship W2008933596A5019337932 @default.
• W2008933596 hasAuthorship W2008933596A5057701424 @default.
• W2008933596 hasAuthorship W2008933596A5061026876 @default.
• W2008933596 hasAuthorship W2008933596A5090435894 @default.
• W2008933596 hasConcept C126322002 @default.
• W2008933596 hasConcept C2776694085 @default.
• W2008933596 hasConcept C2776960273 @default.
• W2008933596 hasConcept C2777063308 @default.
• W2008933596 hasConcept C2777583451 @default.
• W2008933596 hasConcept C2777767877 @default.
• W2008933596 hasConcept C2778461978 @default.
• W2008933596 hasConcept C2778729363 @default.
• W2008933596 hasConcept C2778850193 @default.
• W2008933596 hasConcept C2779171977 @default.
• W2008933596 hasConcept C3019892230 @default.
• W2008933596 hasConcept C71924100 @default.
• W2008933596 hasConcept C90924648 @default.
• W2008933596 hasConceptScore W2008933596C126322002 @default.
• W2008933596 hasConceptScore W2008933596C2776694085 @default.
• W2008933596 hasConceptScore W2008933596C2776960273 @default.
• W2008933596 hasConceptScore W2008933596C2777063308 @default.
• W2008933596 hasConceptScore W2008933596C2777583451 @default.
• W2008933596 hasConceptScore W2008933596C2777767877 @default.
• W2008933596 hasConceptScore W2008933596C2778461978 @default.
• W2008933596 hasConceptScore W2008933596C2778729363 @default.
• W2008933596 hasConceptScore W2008933596C2778850193 @default.
• W2008933596 hasConceptScore W2008933596C2779171977 @default.
• W2008933596 hasConceptScore W2008933596C3019892230 @default.
• W2008933596 hasConceptScore W2008933596C71924100 @default.
• W2008933596 hasConceptScore W2008933596C90924648 @default.
• W2008933596 hasIssue "12" @default.
• W2008933596 hasLocation W20089335961 @default.
• W2008933596 hasLocation W20089335962 @default.
• W2008933596 hasOpenAccess W2008933596 @default.
• W2008933596 hasPrimaryLocation W20089335961 @default.
• W2008933596 hasRelatedWork W1861808521 @default.
• W2008933596 hasRelatedWork W1988956304 @default.
• W2008933596 hasRelatedWork W1992559636 @default.
• W2008933596 hasRelatedWork W2003258318 @default.
• W2008933596 hasRelatedWork W2093487133 @default.
• W2008933596 hasRelatedWork W2527816261 @default.
• W2008933596 hasRelatedWork W2766609975 @default.
• W2008933596 hasRelatedWork W4250026301 @default.
• W2008933596 hasRelatedWork W4301697663 @default.
• W2008933596 hasRelatedWork W2466010828 @default.
• W2008933596 hasVolume "100" @default.
• W2008933596 isParatext "false" @default.
• W2008933596 isRetracted "false" @default.

• next